
IVERIC bio ISEE
IVERIC bio Gesamtes Eigenkapital | ISEE
Gesamtes Eigenkapital Jährlich IVERIC bio
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 535 M | 361 M | 192 M | 117 M | 124 M | 38 M | -94.6 M | 59.9 M | 129 M | 170 M | -123 M | -102 M | -77.3 M | -52.8 M | -35.1 M | -12 M |
Jährliche Entwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 535 M | -123 M | 76.7 M |
Gesamtes Eigenkapital Vierteljährlich IVERIC bio
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 477 M | 535 M | 260 M | 293 M | 333 M | 361 M | 226 M | 140 M | 167 M | 192 M | 215 M | 238 M | 105 M | 117 M | 89.5 M | 102 M | 114 M | 124 M | 5.43 M | 17.5 M | 28.1 M | 38 M | 43.9 M | -149 M | -132 M | -94.6 M | -36.6 M | 14.5 M | 33.2 M | 59.9 M | 83.1 M | 114 M | 142 M | 129 M | 176 M | 159 M | 207 M | 170 M | 189 M | 170 M | 170 M | -123 M | -123 M | - | - | -102 M | - | - | - |
Quartalsentwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 535 M | -149 M | 120 M |
Gesamtes Eigenkapital anderer Aktien in der Pharmaeinzelhändler
| Name | Gesamtes Eigenkapital | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Kaleido Biosciences
KLDO
|
10.6 M | - | -3.69 % | $ 12.4 M | ||
|
VBI Vaccines
VBIV
|
7.53 M | - | -50.87 % | $ 1.09 M | ||
|
CTI BioPharma Corp.
CTIC
|
-17.6 M | - | - | $ 1.2 B | ||
|
Decibel Therapeutics
DBTX
|
81.8 M | - | - | $ 123 M | ||
|
Arcutis Biotherapeutics
ARQT
|
189 M | $ 26.35 | -3.02 % | $ 3.35 B | ||
|
ObsEva SA
OBSV
|
8.35 M | - | -15.52 % | $ 10.5 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
50.3 M | $ 41.53 | -4.86 % | $ 5.88 B | ||
|
Monopar Therapeutics
MNPR
|
138 M | $ 69.02 | -1.81 % | $ 512 M | ||
|
Poseida Therapeutics
PSTX
|
104 M | - | - | $ 857 M | ||
|
Y-mAbs Therapeutics
YMAB
|
92 M | - | - | $ 382 M | ||
|
Satsuma Pharmaceuticals
STSA
|
46.8 M | - | -0.9 % | $ 36.5 M | ||
|
Anavex Life Sciences Corp.
AVXL
|
94.9 M | $ 0.59 | -11.3 % | $ 50.3 M | ||
|
SpringWorks Therapeutics
SWTX
|
481 M | - | - | $ 3.48 B | ||
|
Axon Enterprise
AXON
|
3.24 B | $ 291.02 | -5.2 % | $ 22.7 B | ||
|
Infinity Pharmaceuticals
INFI
|
-19.1 M | - | -46.98 % | $ 3.57 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M | ||
|
Evelo Biosciences
EVLO
|
-4.99 M | - | -14.46 % | $ 27.9 M | ||
|
Morphic Holding
MORF
|
697 M | - | - | $ 2.42 B | ||
|
Genocea Biosciences
GNCA
|
27.1 M | - | -15.0 % | $ 3.04 M | ||
|
Biogen
BIIB
|
18.3 B | $ 249.55 | 0.98 % | $ 36.6 B | ||
|
Bristol-Myers Squibb Company
BMY
|
18.5 B | $ 58.74 | 0.69 % | $ 119 B | ||
|
Eiger BioPharmaceuticals
EIGR
|
-14.5 M | - | -9.21 % | $ 2.55 M | ||
|
IGM Biosciences
IGMS
|
48.2 M | - | - | $ 76.9 M | ||
|
Merrimack Pharmaceuticals
MACK
|
18.7 M | - | - | $ 216 M | ||
|
Rubius Therapeutics
RUBY
|
15.1 M | - | -33.55 % | $ 7.81 M | ||
|
Mirati Therapeutics
MRTX
|
997 M | - | - | $ 3.3 B | ||
|
InVivo Therapeutics Holdings Corp.
NVIV
|
15.7 M | - | -37.48 % | $ 476 K | ||
|
Bellicum Pharmaceuticals
BLCM
|
2.02 M | - | -9.72 % | $ 5.89 M | ||
|
Orchard Therapeutics plc
ORTX
|
98.3 M | - | 1.02 % | $ 90.8 M | ||
|
La Jolla Pharmaceutical Company
LJPC
|
-66.7 M | - | - | $ 154 M | ||
|
Oyster Point Pharma
OYST
|
99.5 M | - | - | $ 300 M | ||
|
Intercept Pharmaceuticals
ICPT
|
93.1 M | - | - | $ 643 M | ||
|
Chinook Therapeutics
KDNY
|
442 M | - | - | $ 2.6 B | ||
|
Syros Pharmaceuticals
SYRS
|
16.7 M | - | -8.44 % | $ 3.4 M | ||
|
NanoViricides
NNVC
|
8.68 M | $ 1.15 | -2.54 % | $ 23.2 M | ||
|
GT Biopharma
GTBP
|
5.79 M | $ 2.93 | -7.86 % | $ 16.2 M | ||
|
Zymeworks
ZYME
|
249 M | $ 26.41 | -1.68 % | $ 1.36 B | ||
|
Aldeyra Therapeutics
ALDX
|
44.3 M | $ 0.84 | 16.41 % | $ 50.4 M | ||
|
Citius Pharmaceuticals
CTXR
|
67.6 M | $ 0.51 | 1.61 % | $ 5.64 M | ||
|
Cytokinetics, Incorporated
CYTK
|
-660 M | $ 50.7 | -1.48 % | $ 6.09 M | ||
|
DBV Technologies S.A.
DBVT
|
169 M | $ 9.03 | -4.14 % | $ 1.26 B | ||
|
Precision BioSciences
DTIL
|
92.2 M | $ 7.37 | 6.66 % | $ 94.5 M | ||
|
Exelixis
EXEL
|
2.16 B | $ 64.59 | -1.88 % | $ 17.5 B | ||
|
Fennec Pharmaceuticals
FENC
|
35.5 M | $ 13.09 | -2.68 % | $ 374 M | ||
|
Cardiff Oncology
CRDF
|
45.4 M | $ 0.85 | -4.67 % | $ 56.8 M | ||
|
BioNTech SE
BNTX
|
19.2 B | $ 80.87 | -0.63 % | $ 19.5 B | ||
|
Alkermes plc
ALKS
|
1.82 B | $ 44.89 | -2.79 % | $ 7.39 B | ||
|
ANI Pharmaceuticals
ANIP
|
541 M | $ 68.6 | -0.77 % | $ 1.38 B | ||
|
AIM ImmunoTech
AIM
|
-9.78 M | $ 0.11 | -7.75 % | $ 178 K |